AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$KRYS

Krystal Biotech Q3 Earnings Preview (KRYS:NASDAQ)

Krystal Biotech (KRYS) will report Q3 earnings on Nov 2. Analysts expect EPS of $1.92, down 27.8% YoY, and revenue of $126.54M, up 29.4% YoY. The company has beaten estimates in 3 of the last 4 quarters, according to data. (350 characters)

Original reporting
seekingalpha.com
Published Oct 30, 2026, 3:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KRYS
Neutral
medium confidence
Mentioned
$KRYS
Relevance
5/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$KRYSNeutralLow
01

Why it matters

Earnings preview sets expectations; actual results will confirm or revise market sentiment.

02

Market read

The upcoming earnings release is the primary catalyst for KRYS price movement.

03

What to watch

Potential FDA updates or pipeline news not covered in the preview could affect the reaction.

Relevance 5/10Novelty 4/10Timing: pre-market on Nov 2

Background

KRYS is a small-cap biotech with a history of volatile earnings reactions.

Company-level read

Ticker impact

$KRYSNeutralMedium confidence
Context

KRYS is scheduled to report Q3 earnings on Nov 2 with consensus EPS of $1.92 and revenue of $126.54M.

Expected impact

potential volatility as market prices in the earnings outcome

Evidence & confidence

Earnings previews provide a baseline; actual results will drive price direction.

Market effects

Sector

Biotech earnings can influence peer valuations in the sector.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

If the company surprises on the upside, the stock could rally sharply despite modest expectations.

Key entities

  • company
    Krystal Biotech

    Biotech firm listed on NASDAQ under KRYS.

Read at source← All news

Related articles

Med

Krystal Biotech, Inc. Q3 2026 Earnings Call Summary

Krystal Biotech reported 30% YOY revenue growth for VYJUVEK, driven by expanding prescriber base and international launches. Gross margin was 94%, slightly decreased due to international markets. The company announced a $400M share repurchase program and expects international revenue to scale with upcoming launches. Clinical milestones include data readouts and FDA discussions for Gorlin syndrome and Ocular DEB programs. Management revised R&D and SG&A guidance downward to $155M-$165M.

finance.yahoo.com
$KRYSMed

Krystal Biotech Q3 Earnings Call Highlights

Krystal Biotech reported Q3 revenue of $32M for VYJUVEK. Expansion in Europe includes pricing deals in Germany, Japan, and Italy, with launches expected in early 2027. Pipeline updates include promising data for KB113 in Gorlin syndrome and delays in other programs. Q3 gross margin was 94%, with adjusted expense guidance lowered to $155M-$165M. The board approved a $400M share buyback program.

finance.yahoo.com